Literature DB >> 26932730

Renal Function Alters Antihypertensive Regimens in Type 2 Diabetic Patients.

Larry A Weinrauch1,2, George Bayliss3, Alissa R Segal4, Jiankang Liu5, Eric Wisniewski4, John A D'Elia4.   

Abstract

To determine the prevalence of multidrug antihypertensive therapy (MDAT), records were evaluated for patients with both type 2 diabetes and hypertension during a 5-year period at Joslin Diabetes Center. Hypertension control was defined as requiring multiple drugs if three or more antihypertensive drugs were used, one of which must be a diuretic (unless patient is receiving dialysis), or use of four or more antihypertensive drugs, one of which a diuretic (unless patient is receiving dialysis) was established. The objective was to determine the prevalence of multidrug requirement for hypertensive therapy in relationship to four levels of renal function estimated by the Modification of Diet in Renal Disease formula for glomerular filtration rate (GFR). Among 10,151 patients, mean estimated GFR was 80 mL/min. Using standard (ASN) classification for renal function, we noted the following breakdown of MDAT use: Estimated GFR Drugs, Mean No. ≥3 Drugs, No. (%) ≥4 Drugs, No. (%) <30 3.1 379 (67) 214 (38) 30-60 2.7 1233 (55) 538 (24) 60-90 2.0 1279 (33) 458 (12) >90 1.5 600 (17) 185 (5) Prevalence of multidrug antihypertensive therapy is markedly increased in the presence of reduced renal function.
© 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26932730      PMCID: PMC8032193          DOI: 10.1111/jch.12776

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  32 in total

1.  Incidence and prognosis of resistant hypertension in hypertensive patients.

Authors:  Stacie L Daugherty; J David Powers; David J Magid; Heather M Tavel; Frederick A Masoudi; Karen L Margolis; Patrick J O'Connor; Joe V Selby; P Michael Ho
Journal:  Circulation       Date:  2012-02-29       Impact factor: 29.690

2.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

3.  Do dipeptidyl peptidase-4 inhibitors increase the risk of heart failure?

Authors:  Deepak L Bhatt; Matthew A Cavender
Journal:  JACC Heart Fail       Date:  2014-07-02       Impact factor: 12.035

4.  Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients.

Authors:  Luca De Nicola; Francis B Gabbai; Rajiv Agarwal; Paolo Chiodini; Silvio Borrelli; Vincenzo Bellizzi; Felice Nappi; Giuseppe Conte; Roberto Minutolo
Journal:  J Am Coll Cardiol       Date:  2013-04-23       Impact factor: 24.094

5.  Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk.

Authors:  F Folli; C R Kahn; H Hansen; J L Bouchie; E P Feener
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

6.  Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes.

Authors:  Julie A Lovshin; Annette Barnie; Ariana DeAlmeida; Alexander Logan; Bernard Zinman; Daniel J Drucker
Journal:  Diabetes Care       Date:  2014-11-20       Impact factor: 19.112

7.  Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.

Authors:  Ihab Hajjar; Theodore A Kotchen
Journal:  JAMA       Date:  2003-07-09       Impact factor: 56.272

8.  Prevalence of apparent treatment-resistant hypertension among individuals with CKD.

Authors:  Rikki M Tanner; David A Calhoun; Emmy K Bell; C Barrett Bowling; Orlando M Gutiérrez; Marguerite R Irvin; Daniel T Lackland; Suzanne Oparil; David Warnock; Paul Muntner
Journal:  Clin J Am Soc Nephrol       Date:  2013-07-18       Impact factor: 8.237

9.  Resistant hypertension in patients with type 2 diabetes: clinical correlates and association with complications.

Authors:  Anna Solini; Giacomo Zoppini; Emanuela Orsi; Cecilia Fondelli; Roberto Trevisan; Monica Vedovato; Franco Cavalot; Olga Lamacchia; Maura Arosio; Marco G Baroni; Giuseppe Penno; Giuseppe Pugliese
Journal:  J Hypertens       Date:  2014-12       Impact factor: 4.844

10.  Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study.

Authors:  Costas Tsioufis; Alexandros Kasiakogias; Athanasios Kordalis; Kyriakos Dimitriadis; Costas Thomopoulos; Dimitrios Tsiachris; Panagiotis Vasileiou; Michalis Doumas; Thomas Makris; Vasilios Papademetriou; Ioannis Kallikazaros; George Bakris; Christodoulos Stefanadis
Journal:  J Hypertens       Date:  2014-02       Impact factor: 4.844

View more
  5 in total

Review 1.  The Diabetic Cardiorenal Nexus.

Authors:  John A D'Elia; George P Bayliss; Larry A Weinrauch
Journal:  Int J Mol Sci       Date:  2022-07-01       Impact factor: 6.208

2.  Treating Hypertension in Diabetic Patients With Advanced Chronic Kidney Disease: What Should We Have in Mind?

Authors:  Panagiotis I Georgianos; Elias V Balaskas; Pantelis E Zebekakis
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-05-11       Impact factor: 3.738

3.  Renal Function Alters Antihypertensive Regimens in Type 2 Diabetic Patients.

Authors:  Larry A Weinrauch; George Bayliss; Alissa R Segal; Jiankang Liu; Eric Wisniewski; John A D'Elia
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-03-02       Impact factor: 3.738

4.  Does diabetes impact therapeutic immunomodulation therapy decisions for kidney transplant recipients? Data from the Folic Acid for Vascular Outcome Reduction in Transplant (FAVORIT) trial.

Authors:  Larry A Weinrauch; John A D'Elia; Matthew R Weir; Suphamai Bunnapradist; Peter Finn; Jiankang Liu; Brian Claggett; Anthony P Monaco
Journal:  Int J Nephrol Renovasc Dis       Date:  2017-08-18

5.  Changes in treatment of hyperglycemia in a hypertensive type 2 diabetes population as renal function declines.

Authors:  Larry A Weinrauch; Alissa R Segal; George P Bayliss; Jiankang Liu; Eric Wisniewski; John A D'Elia
Journal:  Clin Kidney J       Date:  2017-05-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.